Isolated BCL2 rearrangement in DLBCL (no MYC partner) — common in GCB-DLBCL transformed f...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BCL2-REARRANGEMENT-DLBCL-NOS |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BCL2-REARRANGEMENT |
|---|---|
| Variant | t(14;18) IGH/BCL2 isolated (single-hit) |
| Disease | DIS-DLBCL-NOS |
| ESCAT tier | IIIB |
| Recommended combinations | R-CHOP / pola-R-CHP per usual DLBCL algorithm |
| Evidence summary | Isolated BCL2 rearrangement in DLBCL (no MYC partner) — common in GCB-DLBCL transformed from FL. Not equivalent to DH lymphoma. Treat per DLBCL-NOS algorithm; venetoclax investigational. |
Notes
ESCAT IIIB. Distinct entity from HGBL-DH (which requires concurrent MYC-R).
Used By
No reverse references found in the YAML corpus.